Portola Pharmaceuticals Inc (PTLA.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|70||2010||IndependentChairman of the Board|
|52||2010||Chief Executive Officer, Director|
|53||2013||Chief Financial Officer, Executive Vice President|
|65||2011||Executive Vice President - Research & Development|
|45||2015||Executive Vice President, Chief Commercial and Business officer|
- BRIEF-Portola Pharmaceuticals Announces Results Of CHMP Oral Explanations For Andexanet Alfa And Betrixaban
- BRIEF-Portola Pharma Says FDA will extend review of AndexXa by 90 days
- BRIEF-U.S. FDA Approves Prior Approval Supplement For Launch Of Portola Pharmaceuticals' Betrixaban
- BRIEF-Portola Provides Update On European Marketing Authorization Application For Betrixaban
- BRIEF-Portola Pharmaceuticals provides update on Bevyxxa commercial launch